Adjuvant System

Adjuvant System designates combinations of multiple immunostimulatory components formulated together to enhance vaccine immune responses through complementary mechanisms, providing greater immunogenicity than individual components alone through synergistic activation of innate immune pathways stimulating adaptive responses.

The vaccine industry develops adjuvant systems providing improved protection through stronger, broader, or more durable immune responses compared to single-component adjuvants. AS01 combining liposomes, MPL, and QS-21 drives potent CD4+ T cell and antibody responses supporting approved malaria and shingles vaccines. AS03 squalene-based emulsion enhances influenza vaccine immunogenicity enabling antigen dose sparing during pandemic responses. Combination adjuvants may activate multiple pattern recognition receptor pathways synergistically amplifying dendritic cell activation. Safety assessment evaluates reactogenicity and systemic effects of combined immunostimulation. Regulatory requirements address adjuvant system characterisation, mechanism, and clinical safety. As vaccine development targets challenging pathogens requiring specific immunity types, adjuvant system design continues advancing through understanding of optimal innate immune activation pathways.